GlassScriptPhysician profile
Mark V Sivieri
NPI 1992701742
$2,211.64
in general payments reported to CMS, 2019-2025
39 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $203 · 2021: $408 · 2022: $486 · 2023: $228 · 2024: $297 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851 · Consulting Fee: $22.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.66 |
| Consulting Fee | $22.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.95 | 2019-2025 | Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.94 | 2022-2025 | Xifaxan, Trulance |
| Csl Behring | $164.77 | 2019-2023 | Hizentra |
| Grifols USA, LLC | $156.12 | 2019-2024 | Xembify |
| Abbott Laboratories | $101.09 | 2019-2025 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $90.75 | 2021-2022 | |
| Antares Pharma, INC. | $89.09 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Ibsa Pharma INC. | $73.14 | 2020-2024 | Tirosint, Tirosint, Licart |
| Amarin Pharma, INC. | $70.29 | 2020-2022 | |
| Redhill Biopharma INC. | $58.76 | 2021-2022 | |
| Acella Pharmaceuticals, LLC | $55.42 | 2022-2025 | NP Thyroid 60 |
| Exact Sciences Corporation | $45.10 | 2024 | Cologuard Collection Kit |
| Romark Laboratories, Lc | $43.09 | 2019-2020 | |
| Pfizer INC. | $35.80 | 2021-2023 | |
| Endo Pharmaceuticals INC. | $35.31 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $34.88 | 2021-2025 | Unithroid |
| Amgen INC. | $29.44 | 2019-2020 | |
| Lilly USA, LLC | $29.06 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.83 | 2022 | |
| Allergan, INC. | $23.73 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $23.10 | 2022 | |
| Genentech USA, INC. | $22.71 | 2020 | |
| Adma Biomanufacturing LLC | $22.57 | 2025 | |
| Astellas Pharma US INC | $21.70 | 2025 | Veozah |
| Digestive Care, INC. | $21.66 | 2024 | Pertzye |
| Pharmaessentia USA Corporation | $20.90 | 2024 | Besremi |
| Halozyme INC | $20.88 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $20.23 | 2022 | |
| Horizon Therapeutics Plc | $19.13 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.91 | 2024 | Strensiq |
| Almatica Pharma LLC | $17.02 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.43 | 2023 | Quviviq |
| Tolmar, INC. | $14.71 | 2024 | |
| Intra-Sana Laboratories | $14.44 | 2022 | |
| Merck Sharp & Dohme LLC | $14.39 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.33 | 2019 | |
| Eisai INC. | $14.02 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.49 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sivieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.